Discovery of dual-action membrane-anchored modulators of incretin receptors

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Fortin, Jean Philippe ^a   Chinnapen, Daniel ^b   Beinborn, Martin ^a   Lencer, Wayne ^b   Kopin, Alan S ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ARGININE; ASPARTIC ACID; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUTAMIC ACID; GLYCINE; INCRETIN; LEUCINE; LYSINE; METHIONINE; GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE RECEPTOR; HORMONE RECEPTOR; PEPTIDE; VENOM;

AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG TARGETING; ENDOCYTOSIS; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; WILD TYPE; CELL LINE; CELL MEMBRANE; CONFOCAL MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; METABOLISM;

CELL LINE; CELL MEMBRANE; ENZYME-LINKED IMMUNOSORBENT ASSAY; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; MICROSCOPY, CONFOCAL; PEPTIDES; RECEPTORS, GASTROINTESTINAL HORMONE; RECEPTORS, GLUCAGON; VENOMS;

EID: 80052868932     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024693     Document Type: Article

References (45)

1. Kim W, Egan JM, (2008) The role of incretins in glucose homeostasis and diabetes treatment. Pharmacological reviews 60: 470-512.
2. Renner S, Fehlings C, Herbach N, Hofmann A, von Waldthausen DC, et al. (2010) Glucose intolerance and reduced proliferation of pancreatic beta-cells in transgenic pigs with impaired glucose-dependent insulinotropic polypeptide function. Diabetes 59: 1228-1238.
3. Lovshin JA, Drucker DJ, (2009) Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 5: 262-269.
4. Tharakan G, Tan T, Bloom S, (2011) Emerging therapies in the treatment of 'diabesity': beyond GLP-1. Trends in pharmacological sciences 32: 8-15.
5. Ahren B, (2009) Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nature reviews Drug discovery 8: 369-385.
6. Drucker DJ, Dritselis A, Kirkpatrick P, (2010) Liraglutide. Nature reviews Drug discovery 9: 267-268.
7. Widenmaier SB, Kim SJ, Yang GK, De Los Reyes T, Nian C, et al. (2010) A GIP receptor agonist exhibits beta-cell anti-apoptotic actions in rat models of diabetes resulting in improved beta-cell function and glycemic control. PloS one 5: e9590.
8. Pratley RE, (2010) GIP: an inconsequential incretin or not? Diabetes care 33: 1691-1692.
9. Irwin N, O'Harte FP, Gault VA, Green BD, Greer B, et al. (2006) GIP(Lys16PAL) and GIP(Lys37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential. Journal of medicinal chemistry 49: 1047-1054.
10. Kulkarni RN, (2010) GIP: no longer the neglected incretin twin? Science translational medicine 2: 49ps47.
11. Parthier C, Kleinschmidt M, Neumann P, Rudolph R, Manhart S, et al. (2007) Crystal structure of the incretin-bound extracellular domain of a G protein-coupled receptor. Proceedings of the National Academy of Sciences of the United States of America 104: 13942-13947.
12. Runge S, Thogersen H, Madsen K, Lau J, Rudolph R, (2008) Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain. The Journal of biological chemistry 283: 11340-11347.
13. Hoare SR, (2005) Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. Drug discovery today 10: 417-427.
14. Choi C, Fortin JP, McCarthy E, Oksman L, Kopin AS, et al. (2009) Cellular dissection of circadian peptide signals with genetically encoded membrane-tethered ligands. Current biology: CB 19: 1167-1175.
15. Fortin JP, Zhu Y, Choi C, Beinborn M, Nitabach MN, et al. (2009) Membrane-tethered ligands are effective probes for exploring class B1 G protein-coupled receptor function. Proceedings of the National Academy of Sciences of the United States of America 106: 8049-8054.
16. Neumann JM, Couvineau A, Murail S, Lacapere JJ, Jamin N, et al. (2008) Class-B GPCR activation: is ligand helix-capping the key? Trends in biochemical sciences 33: 314-319.
17. Parthier C, Reedtz-Runge S, Rudolph R, Stubbs MT, (2009) Passing the baton in class B GPCRs: peptide hormone activation via helix induction? Trends in biochemical sciences 34: 303-310.
18. Fortin JP, Schroeder JC, Zhu Y, Beinborn M, Kopin AS, (2010) Pharmacological characterization of human incretin receptor missense variants. The Journal of pharmacology and experimental therapeutics 332: 274-280.
19. Tseng CC, Zhang XY, (1998) The cysteine of the cytoplasmic tail of glucose-dependent insulinotropic peptide receptor mediates its chronic desensitization and down-regulation. Molecular and cellular endocrinology 139: 179-186.
20. Stenmark H, (2009) Rab GTPases as coordinators of vesicle traffic. Nature reviews Molecular cell biology 10: 513-525.
21. Schwarzmann G, von Coburg A, Mobius W, (2000) Using biotinylated gangliosides to study their distribution and traffic in cells by immunoelectron microscopy. Methods in enzymology 312: 534-562.
22. Summerhill S, Stroud T, Nagendra R, Perros-Huguet C, Trevethick M, (2008) A cell-based assay to assess the persistence of action of agonists acting at recombinant human beta(2) adrenoceptors. Journal of pharmacological and toxicological methods 58: 189-197.
23. Aurora R, Rose GD, (1998) Helix capping. Protein science: a publication of the Protein Society 7: 21-38.
24. Inooka H, Ohtaki T, Kitahara O, Ikegami T, Endo S, et al. (2001) Conformation of a peptide ligand bound to its G-protein coupled receptor. Nature structural biology 8: 161-165.
25. Doan ND, Bourgault S, Dejda A, Letourneau M, Detheux M, et al. (2011) Design and in vitro characterization of PAC1/VPAC1-selective agonists with potent neuroprotective effects. Biochemical pharmacology 81: 552-561.
26. Bourgault S, Vaudry D, Segalas-Milazzo I, Guilhaudis L, Couvineau A, et al. (2009) Molecular and conformational determinants of pituitary adenylate cyclase-activating polypeptide (PACAP) for activation of the PAC1 receptor. Journal of medicinal chemistry 52: 3308-3316.
27. Tseng CC, Zhang XY, (2000) Role of G protein-coupled receptor kinases in glucose-dependent insulinotropic polypeptide receptor signaling. Endocrinology 141: 947-952.
28. Molinari P, Vezzi V, Sbraccia M, Gro C, Riitano D, et al. (2010) Morphine-like opiates selectively antagonize receptor-arrestin interactions. The Journal of biological chemistry 285: 12522-12535.
29. Richardson RM, Marjoram RJ, Barak LS, Snyderman R, (2003) Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. Journal of immunology 170: 2904-2911.
30. Estall JL, Koehler JA, Yusta B, Drucker DJ, (2005) The glucagon-like peptide-2 receptor C terminus modulates beta-arrestin-2 association but is dispensable for ligand-induced desensitization, endocytosis, and G-protein-dependent effector activation. The Journal of biological chemistry 280: 22124-22134.
31. Widmann C, Dolci W, Thorens B, (1997) Internalization and homologous desensitization of the GLP-1 receptor depend on phosphorylation of the receptor carboxyl tail at the same three sites. Molecular endocrinology 11: 1094-1102.
32. Leterrier C, Bonnard D, Carrel D, Rossier J, Lenkei Z, (2004) Constitutive endocytic cycle of the CB1 cannabinoid receptor. The Journal of biological chemistry 279: 36013-36021.
33. Conn PM, Ulloa-Aguirre A, Ito J, Janovick JA, (2007) G protein-coupled receptor trafficking in health and disease: lessons learned to prepare for therapeutic mutant rescue in vivo. Pharmacological reviews 59: 225-250.
34. Waehler R, Russell SJ, Curiel DT, (2007) Engineering targeted viral vectors for gene therapy. Nature reviews Genetics 8: 573-587.
35. Vauquelin G, Charlton SJ, (2010) Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action. British journal of pharmacology 161: 488-508.
36. Vauquelin G, Packeu A, (2009) Ligands, their receptors and...plasma membranes. Molecular and cellular endocrinology 311: 1-10.
37. Clark RB, Allal C, Friedman J, Johnson M, Barber R, (1996) Stable activation and desensitization of beta 2-adrenergic receptor stimulation of adenylyl cyclase by salmeterol: evidence for quasi-irreversible binding to an exosite. Molecular pharmacology 49: 182-189.
38. Russell-Jones D, (2009) Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue. Molecular and cellular endocrinology 297: 137-140.
39. Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, et al. (2000) Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. Journal of medicinal chemistry 43: 1664-1669.
40. Romano R, Bayerl TM, Moroder L, (1993) Lipophilic derivatization and its effect on the interaction of cholecystokinin (CCK) nonapeptide with phospholipids. Biochimica et biophysica acta 1151: 111-119.
41. Day JW, Ottaway N, Patterson JT, Gelfanov V, Smiley D, et al. (2009) A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nature chemical biology 5: 749-757.
42. Pocai A, Carrington PE, Adams JR, Wright M, Eiermann G, et al. (2009) Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 58: 2258-2266.
43. Gault VA, Kerr BD, Harriott P, Flatt P, (2011) Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with type 2 diabetes and obesity. Clinical science.
44. Tibaduiza EC, Chen C, Beinborn M, (2001) A small molecule ligand of the glucagon-like peptide 1 receptor targets its amino-terminal hormone binding domain. The Journal of biological chemistry 276: 37787-37793.
45. Beinborn M, Lee YM, McBride EW, Quinn SM, Kopin AS, (1993) A single amino acid of the cholecystokinin-B/gastrin receptor determines specificity for non-peptide antagonists. Nature 362: 348-350.